Why the study?
Does estradiol replacement therapy inhibit CYP1A2-mediated caffeine metabolism in healthy postmenopausal women?
Does estradiol replacement therapy inhibit CYP1A2-mediated caffeine metabolism in healthy postmenopausal women?
Exogenous estrogen replacement therapy in postmenopausal women significantly inhibits CYP1A2-mediated caffeine metabolism.
Answers are grounded in this paper and cite their sources.
May warrant caution with CYP1A2 substrates in postmenopausal women on estrogen; hypothesis-generating and requires randomized confirmation before practice change.
This study was conducted to investigate the effect of therapeutic estrogen on cytochrome P450 1A2-mediated metabolism in postmenopausal women using caffeine as a model substrate. Twelve healthy postmenopausal women underwent estrogen replacement therapy in the form of estradiol (Estrace). Estradiol was initiated at a dose of 0.5 mg a day and titrated to achieve a steady-state plasma concentration of 50 to 150 pg/ml. Caffeine metabolic ratios (CMR; paraxanthine/caffeine) were assessed both before and after 8 weeks of estrogen replacement. For the 12 subjects, there was a mean reduction in CMR of -29.2 +/- 25.0 (p = 0.0019). Consistent with previous results found in younger women, these results indicate that exogenous estrogen in older women may inhibit CYP1A2-mediated caffeine metabolism.
No takes yet. Share an insight, caveat, or question.
Pollock et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: